TOBacco STOP in Chronic Obstructive Pulmonary Disease-Trial - Study Protocol
Key facts
- Who runs it
- Pradeesh Sivapalan
- Where
- Denmark4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 4
- Started
- 1 Jul 2023
- Ended
- 1 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- High-intensity smoking cessation intervention
- Low-intensity smoking cessation intervention
- Record updated
- 23 February 2023
- Why it stopped
- No funding
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Competent and mature
- Have diagnosed COPD [spirometry verified and evaluated by pulmonary specialist]
- Current daily smoker [Minimum 1 cigarette daily]
- Have smoked minimum 20 pack years (1 pack year = 20 cigarettes daily in 1 year)
- Want to or try to stop smoking
- Do not mind taking varenicline or NRT during the trial
- Are willing to give blood and urine samples according to the protocol
Who cannot take part
- Previously included in the trial
- Are associated with hospital outpatient clinic for COPD disease treatment
- Severe mental illness that is not controlled with medication
- Active cancer disease* *The person can participate if he or she has had a cancer disease that is now referred to as curative/radically treated. Basal cell carcinoma of the skin does not count as an exclusion criterion
- Hospitalized with COPD-exacerbation within the last 24 months
- Have FEV1<50%
- Pregnancy/breastfeeding
- Life expectancy less than 1 year
- Severe linguistic problems or inability to give informed consent
- Active alcohol or substance abuse
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
Cigarette smoking is the leading cause of chronic obstructive pulmonary disease (COPD) and it contributes to the development of many other serious diseases. Acute exacerbations of COPD (AECOPD) often lead to hospitalization. Severe hospitalization-requiring AECOPD carries very high economic costs for the healthcare system, and personal costs for patients. Smoking cessation in COPD for the healthcare system, and personal costs for patients. Smoking cessation in COPD patients is known to improve survival and reduce the number of AECOPD. However, smoking cessation interventions in these patients have only been successful for consistent smoking abstinence in 12 months in approximately 15-20%. Thus, more effective interventions are needed for this patient group.
Aims:
The aim of this study is to determine, among people with chronic obstructive pulmonary disease (COPD), whether a "high-intensive" smoking cessation intervention in comparison to a standard intervention can lead to permanent, >12 months, smoking cessation in a higher proportion.
Methods:
This study is a randomized trial in active smokers with COPD and who have lost less than 50% lung function. A total of 600 participants will be randomly assigned 1:1 to either a standard treatment (guideline-based municipal smoking cessation programme, "low intensity" group), or an intervention group ("high-intensity" group), which consists of group sessions, telephone consultations, behavior design, hotline, "buddy-matching" (smoker matched with COPD patient who stopped). Both groups will receive pharmacological smoking cessation.
Discussion:
The potential benefit of this project is to prevent smoking-related exacerbations of COPD and thereby reduce logistics and costs of hospitalization and treatment of COPD. In addition, the project can potentially benefit from increasing the quality of life and longevity of COPD patients and reducing the risk of developing lung cancer and other smoking-related diseases.
The 2 groups in the trial
- High-intensity groupTreatment being tested
Will receive "high-intensity" intervention, which is a combination of pharmacological (varenicline) and behavioural support, described later.
Treatment: High-intensity smoking cessation intervention
- Low-intensity groupExisting treatment, for comparison
Encouraged to quit smoking via own doctor and is prescribed varenicline.
Treatment: Low-intensity smoking cessation intervention
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Open-label, Superiority, Multicenter, Two-arm Intervention Study of the Effect of "High-intensity" vs. 'Low-intensity' Smoking Cessation Intervention in Active Smokers With COPD
- Publications
- Interventions for preventing weight gain after smoking cessation.The Cochrane database of systematic reviews, 2021
- TOB-STOP-COP (TOBacco STOP in COPd trial): study protocol-a randomized open-label, superiority, multicenter, two-arm intervention study of the effect of "high-intensity" vs. "low-intensity" smoking cessation intervention in active smokers with chronic obstructive pulmonary disease.Trials, 2020
- Record updated
- 23 February 2023